Claims for Patent: 10,053,697

Summary for Patent: 10,053,697

Title:	Programmable alternative splicing devices and uses thereof
Abstract:	Provided herein, among other things, is an RNA that comprises a first exon, a second exon, a third exon and a fourth exon, wherein the RNA is capable of being spliced into; i. a first splicing product comprising the second exon or ii. a splicing second product comprising the third exon, wherein: i. an intron of the RNA, e.g., the intron between the first and second exons of the RNA, comprises an aptamer and ii. binding of a ligand to the aptamer determines whether the RNA is spliced into the first splicing product or the second splicing product. Methods and cells containing the RNA are also described.
Inventor(s):	Smolke Christina D., Mathur Melina
Assignee:	The Board of Trustees of the Leland Stanford Junior University
Application Number:	US14991837
Patent Claims:

Details for Patent 10,053,697

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	June 04, 1986	10,053,697	2036-01-08
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132		10,053,697	2036-01-08
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132		10,053,697	2036-01-08